Please login to the form below

Not currently logged in
Email:
Password:

Spravato

This page shows the latest Spravato news and features for those working in and with pharma, biotech and healthcare.

Stung by critics, J&J says antidepressant Spravato saves money

Stung by critics, J&J says antidepressant Spravato saves money

Responds to ICER cost effectiveness ruling. Johnson &Johnson insists its nasal spray antidepressant Spravato can reduce the cost of caring for treatment-resistant depression (TRD) compared to oral drugs, in a ... For its part, J&J insists its new cost-per

Latest news

  • Depression drug failure adds to Allergan's woes Depression drug failure adds to Allergan's woes

    The misfiring of rapastinel is a major blow for the company’s most important late-stage candidate, and is a clear contrast to J&J’s rival treatment Spravato (esketamine), which

  • J&J’s Spravato breaks depression drought at FDA J&J’s Spravato breaks depression drought at FDA

    The FDA has approved Johnson &Johnson’s Spravato for treatment-resistant depression, making it the first new-mechanism antidepressant to be licensed in decades. ... Spravato should make the add-on therapy much more accessible and affordable, at least

  • FDA panel backs J&J’s new-class antidepressant FDA panel backs J&J’s new-class antidepressant

    The nasal spray formulation of esketamine – a derivative of the anaesthetic ketamine that has the proposed name Spravato – was backed by a 14-2 vote by an FDA advisory committee yesterday

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics